Celldex Therapeutics stock (US15117B1035): focus shifts to funding runway after $345 million equity raise

Celldex Therapeutics shares remain in focus on Nasdaq after the U.S. biotech completed a $345 million stock offering at USD 29 per share in May 2026, bolstering its cash position as it advances barzolvolimab in inflammatory and allergic disease trials.

Celldex Therapeutics is again drawing attention from biotech investors in the United States after the company recently completed a sizable equity financing that strengthened its balance sheet ahead of key clinical milestones.

According to a Celldex Therapeutics press release dated 05/21/2026, the company closed an underwritten public offering of 11,896,750 shares of common stock on Nasdaq at a price of USD 29.00 per share, generating gross proceeds of approximately USD 345 million before underwriting discounts, commissions and expenses, with the deal led by a syndicate of investment banks and targeted at funding ongoing clinical programs and general corporate purposes; Celldex stated that all shares offered were sold in the transaction, which was conducted under its existing shelf registration statement and is intended to extend its cash runway as it advances its pipeline of antibody-based therapies.

As of 06/05/2026, Celldex Therapeutics shares traded on Nasdaq under the ticker CLDX, and recent quote data from Zacks as of 06/05/2026 showed the stock changing hands at around USD 20.91 in regular trading, illustrating that the market price has moved below the May 2026 offering level of USD 29.00 per share, while the company’s primary listing and investor base remain centered in the United States, where U.S. biotech indices and specialist funds provide much of the liquidity for the name.

For German investors following the stock via secondary trading venues, Celldex Therapeutics can also be accessed on platforms such as Tradegate under its Nasdaq ticker, where the shares are quoted in euros and track the movements on the home exchange in the United States, although liquidity and spreads on these German venues typically differ from the primary Nasdaq listing.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: CLDX
• Sector/industry: Biotechnology, immunology-focused therapeutics
• Headquarters/country: Hampton, United States
• Core markets: United States and other major pharmaceutical markets
• Key revenue drivers: Pipeline of antibody-based therapies targeting allergic, inflammatory and oncologic diseases
• Home exchange/listing venue: Nasdaq (CLDX)
• Trading currency: USD

Celldex Therapeutics: core business model

Celldex Therapeutics focuses on discovering and developing targeted monoclonal antibody therapies aimed at immune-driven diseases, with potential future revenues expected to stem primarily from successful late-stage development and potential commercialization or partnering of candidates such as barzolvolimab and other biologics in its pipeline.

Valuation metrics and multiples for Celldex Therapeutics

Given its status as a clinical-stage biotechnology company, Celldex Therapeutics is typically assessed by investors more on the basis of its cash position, burn rate and probability-adjusted pipeline potential than on traditional valuation multiples like price-earnings, as the company does not yet generate material product revenues or positive net income; the sizeable equity raise in May 2026 at USD 29.00 per share, documented in the Celldex press release dated 05/21/2026, provides fresh capital that analysts can incorporate into their models when estimating the company’s enterprise value and projected cash runway.

On 06/05/2026, Zacks reported that Celldex Therapeutics shares were trading at around USD 20.91 with modest intraday percentage changes, implying that the company’s equity value in the market is currently below the recent offering price and highlighting how sentiment around clinical catalysts, broader biotech risk appetite and expectations for the barzolvolimab program can cause notable swings in the implied market capitalization, even when the underlying balance sheet has been bolstered by a completed financing.

For investors considering relative value, commonly used biotech valuation markers such as enterprise value to cash, price to pipeline or comparisons to peers with similar-stage mid- to late-stage antibody assets may be applied to CLDX, but the availability of USD 345 million in gross proceeds from the May 2026 stock sale, as disclosed by Celldex, means that the company’s net cash position after deducting debt and factoring in its reported cash at the time of the offering will be a central component in any discussion of downside protection and funding capacity ahead of pivotal trials.

The shift from an offering price of USD 29.00 per share in the May 2026 deal to trading levels just above USD 20 as referenced by Zacks on 06/05/2026 also offers a reference point for how the market has recalibrated expectations in the weeks after the transaction, with some investors viewing the gap as reflecting general biotech sector volatility on Nasdaq rather than a fundamental change in the company’s prospects, while others may read it as a signal that the valuation assigned at the time of the raise incorporated a higher degree of optimism than the current market is willing to support.

In this context, valuation frameworks for Celldex often hinge on scenario analyses around the commercial potential of barzolvolimab in conditions such as chronic urticaria or other allergic indications, combined with assumptions regarding development timelines, probability of regulatory success and potential peak sales, with the strengthened balance sheet from the May 2026 financing serving to reduce near-term financing risk but not eliminating the inherent development and regulatory risks that remain central to any clinical-stage biotechnology valuation.

Conclusion

The recent USD 345 million stock offering at USD 29.00 per share, completed on 05/21/2026 according to Celldex’s own disclosure, has materially reinforced the company’s financial resources as it advances barzolvolimab and other clinical programs, while also providing a clear reference point for how the market has valued new capital in the stock.

With Celldex Therapeutics shares quoted around USD 20.91 on Nasdaq as of 06/05/2026 based on Zacks data, the current trading level sits below the recent deal price, underscoring how sentiment toward clinical catalysts and the broader biotech environment can influence valuation even after a successful capital raise, and making the interaction between funding runway, clinical progress and investor expectations central to the ongoing investment narrative for CLDX.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.